Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (DE:RHO6)
:RHO6
RHO6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€27.10 - €39.50
Previous CloseN/A
Volume0.00
Average Volume (3M)264.00
Market Cap
€256.35B
Enterprise Value€249.65B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)29.0
Beta0.15
Next Earnings
Jul 24, 2025EPS Estimate
1.4Last Dividend Ex-Date
Mar 14, 2024Dividend Yield2.04%
Share Statistics
EPS (TTM)1.36
Shares Outstanding5,620,501,500
10 Day Avg. Volume608
30 Day Avg. Volume264
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€39.82Price Target Upside2.00% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Business PerformanceThe Roche model was updated and numbers raised post recent business trends.
Positive Data UpdateUpdated Part 1 data showed that 3.6 mg/kg of trontinemab showed a mean amyloid reduction of 107 centiloid units after 7 doses at 28 weeks with no cases of ARIA.
Therapeutic PotentialGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Drug TolerabilityCT-388 and CT-996 tolerability is poor in early weight loss trials.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Safety ConcernsThere was a case of fatal cerebral macrohemorrhage in Part 2.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.63% Mutual Funds
0.11% Other Institutional Investors
99.22% Public Companies and Individual Investors
RHO6 FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was €27.10 and its highest was €39.50 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is €256.35B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 24, 2025 which is in 151 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 30, 2025. The company reported €1.126 earnings per share for the quarter, beating the consensus estimate of €1.061 by €0.065.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of €0.836 which represents an annual dividend yield of 2.04%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 1.4.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 5,620,501,500 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of €1.126 in its last earnings report, beating expectations of €1.061. Following the earnings report the stock price went down -1.995%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in DE:RHO6
---
Roche Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€39.82 (2.00% Upside)
€39.82 (2.00% Upside)
Blogger Sentiment
Bullish
DE:RHO6 Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.16%
12-Months-Change
Fundamentals
Return on Equity
26.76%
Trailing 12-Months
Asset Growth
4.51%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
RHO6 Company Deck
---
RHO6 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Roche reported strong financial results for 2024 with significant growth in sales and core operating profit. The company successfully managed the decline in COVID-19 sales through robust base business growth and achieved key milestones in both the pharma and diagnostics segments. However, the net income decline due to impairments and challenges in some markets posed concerns. Overall, the sentiment leans positive with a strong pipeline and strategic focus on future growth.Read More>---
RHO6 Stock 12 Month Forecast
Average Price Target
€39.82
▲(2.00% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Eli Lilly & Co
―
Johnson & Johnson
―
Merck & Company
―
Pfizer
―
Best Analysts Covering RHO6
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-5.80%
initiated a sell rating a year ago
Copying Mark Purcell's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.80% per trade.
---